Loading…
Ensuring Equal Access to Treatments Act of 2017
Legislative Progress
Momentum (last 30 days)
0
score
0 actions · 0 new cosponsors · 0 votes
Speed vs cohort
49pct
4d open
vs 7,393 other HR bills in the 115th — cohort avg 50d
Ensuring Equal Access to Treatments Act of 2017 This bill modifies provisions related to Medicare coverage and payment for new drugs, devices, and technology, including with respect to the new-technology add-on program.
These links require the bill number to appear in the filing's source-reported specific issue text. Client expenses and lobbying-firm income are separate disclosure fields.
Filing registrants (4)
2018 · second_quarter · Medicare/Medicaid
Issues related to packaging of certain drug therapies under Medicare Part B, including H.R. 4679 - Ensuring Equal Access to Treatments Act of 2017.
Referred to the Subcommittee on Health.
Referred to the Committee on Ways and Means, and in addition to the Committee on Energy and Commerce, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
Introduced in House
Congress.gov source codes: 1000, Intro-H
Bills with similar content found using semantic analysis.
Sources: Congress.gov
Client expense: Not reported · Firm income: $60,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2018 · fourth_quarter · Medicare/Medicaid
H.R.1838/S.1001 - Ambulatory Surgical Center Quality and Access Act of 2017 H.R.1017/S.479 - Removing Barriers to Colorectal Cancer Screening Act of 2017 H.R.4679 - Ensuring Equal Access to Treatments Act of 2017 H.R.5804 - Post-Surgical Injections as an Opioid Alternative Act H.R.5809 - Postoperative Opioid Prevention Act of 2018 H.R.6138 - ASC Payment Transparency Act of 2018 H.R.5674 - VA MISSION Act of 2018 H.R.4783/S.2239 - Veterans Deserve Better Act Reform of Medicare payments to ASCs Reform of Medicare regulations dealing with ASCs
Client expense: $172,085 · Firm income: Not reported
Government targets: Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
2018 · third_quarter · Medicare/Medicaid
H.R.1838/S.1001 - Ambulatory Surgical Center Quality and Access Act of 2017 H.R.1017/S.479 - Removing Barriers to Colorectal Cancer Screening Act of 2017 H.R.4679 - Ensuring Equal Access to Treatments Act of 2017 H.R.5804 - Post-Surgical Injections as an Opioid Alternative Act H.R.5809 - Postoperative Opioid Prevention Act of 2018 H.R.6138 - ASC Payment Transparency Act of 2018 H.R.5674 - VA MISSION Act of 2018 H.R.4783/S.2239 - Veterans Deserve Better Act Reform of Medicare payments to ASCs Reform of Medicare regulations dealing with ASCs
Client expense: $165,615 · Firm income: Not reported
Government targets: Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
2018 · third_quarter · Medicare/Medicaid
Issues related to packaging of certain drug therapies under Medicare Part B, including H.R. 4679 - Ensuring Equal Access to Treatments Act of 2017.
Client expense: Not reported · Firm income: $60,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2018 · second_quarter · Medicare/Medicaid
H.R.1838/S.1001 - Ambulatory Surgical Center Quality and Access Act of 2017 H.R.1017/S.479 - Removing Barriers to Colorectal Cancer Screening Act of 2017 H.R.4679 - Ensuring Equal Access to Treatments Act of 2017 H.R.1628 - American Health Care Act of 2017 H.R.5804 - Post-Surgical Injections as an Opioid Alternative Act H.R.5809 - Postoperative Opioid Prevention Act of 2018 H.R.6138 - ASC Payment Transparency Act of 2018 H.R.5674 - VA MISSION Act of 2018 H.R.4783/S.2239 - Veterans Deserve Better Act Reform of Medicare payments to ASCs Reform of Medicare regulations dealing with ASCs
Client expense: $225,085 · Firm income: Not reported
Government targets: Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
2018 · second_quarter · Medicare/Medicaid
Issues related to packaging of certain drug therapies under Medicare Part B, including H.R. 4679 - Ensuring Equal Access to Treatments Act of 2017.
Client expense: Not reported · Firm income: $60,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2018 · first_quarter · Medicare/Medicaid
H.R.1838/S.1001 - Ambulatory Surgical Center Quality and Access Act of 2017 H.R.1017/S.479 - Removing Barriers to Colorectal Cancer Screening Act of 2017 H.R.4679 - Ensuring Equal Access to Treatments Act of 2017 H.R.1628 - American Health Care Act of 2017 Reform of Medicare payments to ASCs Reform of Medicare regulations dealing with ASCs
Client expense: $180,599 · Firm income: Not reported
Government targets: Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
2018 · first_quarter · Health Issues
Education about the value of innovative new medicines and the Orphan Drug Act. H.R.195: Making further continuing appropriations for the fiscal year ending September 30, 2018, and for other purposes, as it relates to the HEALTHY KIDS Act CHIP reauthorization. Reauthorization of the Animal Drug User Fee Act (ADUFA). Right to Try legislation. H.R.4679: Ensuring Equal Access to Treatments Act of 2017.
Client expense: Not reported · Firm income: $60,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2018 · first_quarter · Health Issues
Education about the value of innovative new medicines and the Orphan Drug Act. H.R.195: Making further continuing appropriations for the fiscal year ending September 30, 2018, and for other purposes, as it relates to the HEALTHY KIDS Act CHIP reauthorization. Reauthorization of the Animal Drug User Fee Act (ADUFA). Right to Try legislation. H.R.4679: Ensuring Equal Access to Treatments Act of 2017.
Client expense: Not reported · Firm income: $60,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2018 · first_quarter · Health Issues
Education about the value of innovative new medicines and the Orphan Drug Act. H.R.195: Making further continuing appropriations for the fiscal year ending September 30, 2018, and for other purposes, as it relates to the HEALTHY KIDS Act CHIP reauthorization. Reauthorization of the Animal Drug User Fee Act (ADUFA). Right to Try legislation. H.R.4679: Ensuring Equal Access to Treatments Act of 2017.
Client expense: Not reported · Firm income: $60,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2018 · first_quarter · Medicare/Medicaid
Issues related to packaging of certain drug therapies under Medicare Part B, including H.R. 4679 - Ensuring Equal Access to Treatments Act of 2017 and H.R. 4683 - To amend title XVIII of the Social Security Act to revise the NTAP period under the Medicare inpatient prospective payment system and the pass-through period under the Medicare outpatient prospective payment system.
Client expense: Not reported · Firm income: $60,000
2017 · fourth_quarter · Medicare/Medicaid
Issues related to deficit reduction and Medicare Issues related to value-based health care and Medicare program integrity, including changes to the Stark laws and Anti-Kickback Statute Issues relating to payment reform, ACOs and Bundling Issues related to the CMS program for durable medical equipment Issues related to the development of Medicare payments for telehealth and remote monitoring services Issues related to applying the unique device identifier to Medicare claims forms S. 787 Telehealth Innovation and Improvement Act Issues related to Ensuring Access to Critical Breakthrough Products Act H.R. 3635, S. 794 Local Coverage Determination Clarification Act of 2016 Issues related to Patient Access to Medicare Protection Act H.R. 4679 "Ensuring Equal Access to Treatments Act of 2017 H.R. 4683 related to NTAP Medicare payments
Client expense: $1,010,000 · Firm income: Not reported
2017 · fourth_quarter · Medicare/Medicaid
H.R.1838 - Ambulatory Surgical Center Quality and Access Act of 2017 H.R.1017/S.479 - Removing Barriers to Colorectal Cancer Screening Act of 2017 H.R.4679 - Ensuring Equal Access to Treatments Act of 2017 H.R.1628 - American Health Care Act of 2017 Reform of Medicare payments to ASCs Reform of Medicare regulations dealing with ASCs
Client expense: $229,218 · Firm income: Not reported
Government targets: Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
2017 · fourth_quarter · Medicare/Medicaid
Issues related to packaging of certain drug therapies under Medicare Part B, including H.R. 4679 - Ensuring Equal Access to Treatments Act of 2017 and H.R. 4683 - To amend title XVIII of the Social Security Act to revise the NTAP period under the Medicare inpatient prospective payment system and the pass-through period under the Medicare outpatient prospective payment system.
Client expense: Not reported · Firm income: $20,000
2017 · fourth_quarter · Health Issues
Education about the value of innovative new medicines and the Orphan Drug Act. H.R.3922: CHAMPIONING HEALTHY KIDS Act. H.R.4679: Ensuring Equal Access to Treatments Act of 2017. Education about the 340(b) program.
Client expense: Not reported · Firm income: $60,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
Government targets: HOUSE OF REPRESENTATIVES, SENATE
Government targets: HOUSE OF REPRESENTATIVES, SENATE
Government targets: HOUSE OF REPRESENTATIVES, SENATE